STING agonist
-
October 16, 2018
TLR and STING Agonists: A New Venture in Cancer Immunotherapy
Emma Shtivelman, PhDImmunotherapy includes a number of strategies that harness the immune system to help treat disease. Immunotherapy for cancer, as we know it, now relies on the activation of specific immune system cells known as T cells. Cancer drugs called immune checkpoint inhibitors act by removing the brakes imposed on T cells by tumors or by the body’s natural mechanisms for limiting their activation to… Read more »